Evidence map›Paper›PMID 40932470›Full record

ArticleFuture oncology (London, England)2025

PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a

Alison M Schram, Marc Fellous, Kim LeDuke, Anita Schmid, Ecaterina E Dumbrava

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04585750 (A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04585750 phase1 / phase2recruitingnot on this map

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

TypeinterventionalSponsorPMV Pharmaceuticals, IncRan2020 to 2027Enrolled300ConditionsAdvanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid TumorArmsrezatapopt, pembrolizumab
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alison M SchramDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6070-2413
Marc FellousPMV Pharmaceuticals, Inc, Princeton, NJ, USA.
Kim LeDukePMV Pharmaceuticals, Inc, Princeton, NJ, USA.
Anita SchmidPMV Pharmaceuticals, Inc, Princeton, NJ, USA.
Ecaterina E DumbravaMD Anderson Cancer Center, The University of Texas, Houston, TX, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

CLINICAL

trial registrationNCT04585750 (ClinicalTrials.gov).

Indexed as

Antineoplastic AgentsMutationNeoplasmsTumor Suppressor Protein p53Clinical Trials, Phase II as TopicFemaleHumansNeoplasm MetastasisTreatment OutcomeAntineoplastic AgentsTP53 protein, humanTumor Suppressor Protein p53cancerclinical trialp53Phase 2reactivatorRezatapoptsolid tumorsTP53 Y220C

Identifiers

PMID40932470
PMCPMC12520105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.